Allogene Therapeutics, Inc. (ALLO)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allogene Therapeutics, Inc. (“Allogene” or the “Company”) (NASDAQ: ALLO). The investigation concerns whether Allogene and certain of its officers and/or directors have violated federal securities laws.

 

On October 7, 2021, post-market, Allogene issued a press release reporting that the U.S. Food and Drug Administration (“FDA”) had placed a hold on the Company’s clinical trials of allogeneic CAR T (AlloCAR T™) therapies for cancer.  The press release stated that the clinical hold “follows the Company’s notification to the FDA of a chromosomal abnormality in an ALPHA2 study patient which was detected in a bone marrow biopsy undertaken to assess pancytopenia (low blood counts)” and that “[a] n investigation is underway to further characterize the observed abnormality, including any clinical relevance, evidence of clonal expansion, or potential relationship to gene editing.  On this news, Allogene’s stock price dropped sharply during intraday trading on October 8, 2021, damaging investors.

 

If you are aware of any facts relating to this investigation, or purchased Allogene shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.